VIS649(西贝普仑单抗)在健康志愿者中的安全性、耐受性、药代动力学和药效学:一种APRIL中和性IgG2单克隆抗体
这项首次人体、随机、双盲、单次递增剂量1期研究在健康成人中评估VIS649(西贝普仑单抗)的安全性、药代动力学和药效学。51名参与者随机接受静脉VIS649(0.5、2.0、6.0、12.0 mg/kg)或安慰剂,另有队列接受VIS649 6.0 mg/kg或安慰剂后行破伤风/白喉疫苗挑战。VIS649安全、耐受良好,可逆性抑制APRIL及多种免疫球蛋白,且不丧失抗原特异性疫苗接种反应。
要点
- VIS649在健康志愿者中安全、耐受良好,无严重不良事件或导致停药的不良事件。
- VIS649呈非线性药代动力学,半衰期随剂量增加而延长,药物暴露增加大于剂量比例。
- 血清APRIL、IgA、Gd-IgA1、IgG和IgM呈剂量依赖性可逆抑制,恢复时间呈剂量反应。
核心结论
- VIS649安全、耐受良好,可逆性抑制APRIL及多种免疫球蛋白,且不丧失抗原特异性疫苗接种反应;值得进一步临床开发用于IgA肾病。
研究设计与样本
- 1期、首次人体、随机、双盲、单次递增剂量研究,在健康成人中评估VIS649的安全性、药代动力学和药效学。
- 共51名参与者随机、给药并纳入安全性分析:每个VIS649剂量组7名,安慰剂组8名,VIS649+疫苗组10名,安慰剂+疫苗组5名。
- VIS649序贯静脉给药队列剂量为0.5、2.0、6.0、12.0 mg/kg;另有一队列接受VIS649 6.0 mg/kg或安慰剂后行破伤风/白喉疫苗挑战。
主要发现
- 无严重不良事件,也无导致研究终止的不良事件。
- VIS649呈非线性药代动力学:半衰期随剂量增加而延长,药物暴露增加大于剂量比例。
- 血清APRIL、IgA、半乳糖缺陷型(Gd)IgA1、IgG和IgM呈剂量依赖性可逆抑制,恢复时间呈剂量反应。
- 破伤风和白喉血清IgG滴度在回忆疫苗接种后升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: VIS649 (sibeprenlimab), a humanized IgG2 monoclonal antibody that inhibits APRIL, is being developed as a potential treatment for IgA nephropathy (IgAN). This phase 1, first-in-human, randomized, double-blind, single ascending dose study aimed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of VIS649 in healthy adults. METHODS: Participants were randomized to VIS649 (sequential i.v. dosing cohorts: 0.5, 2.0, 6.0, 12.0 mg/kg) or placebo; a further cohort received VIS649 6.0 mg/kg or placebo followed by a tetanus/diphtheria vaccine challenge. RESULTS: A total of 51 participants were randomized, dosed, and analyzed for safety (7 for each VIS649 dose; 8 for placebo; 10 for VIS649 + vaccine; 5 for placebo + vaccine). There were no serious adverse events (AEs) or AEs leading to study discontinuation. VIS649 had nonlinear PK: half-life increased with dose and drug exposure increased in a greater than dose-proportional manner. Serum APRIL, IgA, galactose-deficient (Gd) IgA1, IgG, and IgM were reversibly suppressed in a dose-dependent manner, with a dose-response in time to recovery. Tetanus and diphtheria serum IgG titers increased after recall vaccination. CONCLUSION: VIS649 was safe, well tolerated, and reversibly suppressed APRIL and various immunoglobulins, without loss of antigen-specific vaccination response. Further clinical development of VIS649 for IgAN is warranted. Trial registration: ClinicalTrials.gov: NCT03719443.
引用
- Mathur M, Barratt J, Suzuki Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022. PMID: 35570983. doi:10.1016/j.ekir.2022.01.1073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。